The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

Shares of Sanofi SNY fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational ...

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Sanofi ( ($SNY) ) has shared an announcement. Sanofi announced on December 15, 2025, that the U.S. regulatory review process for tolebrutinib, a ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Results from the PERSEUS Phase III study showed that tolebrutinib did not meet its primary endpoint in delaying time to ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...